Annual Cash & Cash Equivalents
$14.31 M
-$32.02 M-69.11%
31 December 2023
Summary:
Inovio Pharmaceuticals annual cash & cash equivalents is currently $14.31 million, with the most recent change of -$32.02 million (-69.11%) on 31 December 2023. During the last 3 years, it has fallen by -$236.42 million (-94.29%). INO annual cash & cash equivalents is now -94.29% below its all-time high of $250.73 million, reached on 31 December 2020.INO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$21.69 M
-$12.70 M-36.94%
30 September 2024
Summary:
Inovio Pharmaceuticals quarterly cash and cash equivalents is currently $21.69 million, with the most recent change of -$12.70 million (-36.94%) on 30 September 2024. Over the past year, it has increased by +$2.88 million (+15.33%). INO quarterly cash and cash equivalents is now -91.35% below its all-time high of $250.73 million, reached on 31 December 2020.INO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -69.1% | +15.3% |
| 3 y3 years | -94.3% | -68.1% |
| 5 y5 years | -39.6% | +36.8% |
INO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -94.3% | at low | -69.5% | +51.5% |
| 5 y | 5 years | -94.3% | at low | -91.3% | +51.5% |
| alltime | all time | -94.3% | +1534.8% | -91.3% | +2773.3% |
Inovio Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $21.69 M(-36.9%) |
| June 2024 | - | $34.39 M(+75.5%) |
| Mar 2024 | - | $19.60 M(+37.0%) |
| Dec 2023 | $14.31 M(-69.1%) | $14.31 M(-23.9%) |
| Sept 2023 | - | $18.80 M(-64.3%) |
| June 2023 | - | $52.71 M(+86.7%) |
| Mar 2023 | - | $28.24 M(-39.0%) |
| Dec 2022 | $46.33 M(-34.9%) | $46.33 M(+110.7%) |
| Sept 2022 | - | $21.99 M(-46.5%) |
| June 2022 | - | $41.10 M(-30.3%) |
| Mar 2022 | - | $59.01 M(-17.1%) |
| Dec 2021 | $71.14 M(-71.6%) | $71.14 M(+4.7%) |
| Sept 2021 | - | $67.94 M(+15.3%) |
| June 2021 | - | $58.93 M(-29.5%) |
| Mar 2021 | - | $83.63 M(-66.6%) |
| Dec 2020 | $250.73 M(+1029.6%) | $250.73 M(+40.3%) |
| Sept 2020 | - | $178.70 M(-17.1%) |
| June 2020 | - | $215.43 M(+36.0%) |
| Mar 2020 | - | $158.45 M(+613.9%) |
| Dec 2019 | $22.20 M(-6.3%) | $22.20 M(+40.0%) |
| Sept 2019 | - | $15.85 M(-19.7%) |
| June 2019 | - | $19.74 M(-5.0%) |
| Mar 2019 | - | $20.78 M(-12.3%) |
| Dec 2018 | $23.69 M(-0.4%) | $23.69 M(+22.1%) |
| Sept 2018 | - | $19.40 M(+28.6%) |
| June 2018 | - | $15.09 M(-59.8%) |
| Mar 2018 | - | $37.51 M(+57.7%) |
| Dec 2017 | $23.79 M(+24.3%) | $23.79 M(+2.2%) |
| Sept 2017 | - | $23.28 M(-2.4%) |
| June 2017 | - | $23.86 M(+4.2%) |
| Mar 2017 | - | $22.90 M(+19.7%) |
| Dec 2016 | $19.14 M(-66.8%) | $19.14 M(-17.7%) |
| Sept 2016 | - | $23.25 M(-18.3%) |
| June 2016 | - | $28.45 M(-31.6%) |
| Mar 2016 | - | $41.62 M(-27.8%) |
| Dec 2015 | $57.63 M(+42.1%) | $57.63 M(-32.6%) |
| Sept 2015 | - | $85.47 M(+21.6%) |
| June 2015 | - | $70.30 M(+168.9%) |
| Mar 2015 | - | $26.15 M(-35.5%) |
| Dec 2014 | $40.54 M(+20.2%) | $40.54 M(-42.6%) |
| Sept 2014 | - | $70.67 M(-20.2%) |
| June 2014 | - | $88.54 M(-10.4%) |
| Mar 2014 | - | $98.77 M(+192.9%) |
| Dec 2013 | $33.72 M(+497.2%) | $33.72 M(+2.0%) |
| Sept 2013 | - | $33.07 M(+219.4%) |
| June 2013 | - | $10.35 M(-48.5%) |
| Mar 2013 | - | $20.09 M(+255.8%) |
| Dec 2012 | $5.65 M(-67.5%) | $5.65 M(+23.0%) |
| Sept 2012 | - | $4.59 M(-22.9%) |
| June 2012 | - | $5.95 M(-46.5%) |
| Mar 2012 | - | $11.13 M(-35.9%) |
| Dec 2011 | $17.35 M | $17.35 M(-31.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2011 | - | $25.30 M(-17.3%) |
| June 2011 | - | $30.59 M(-17.7%) |
| Mar 2011 | - | $37.18 M(+85.9%) |
| Dec 2010 | $20.00 M(-34.0%) | $20.00 M(+3.1%) |
| Sept 2010 | - | $19.39 M(+29.7%) |
| June 2010 | - | $14.95 M(-15.6%) |
| Mar 2010 | - | $17.71 M(-41.5%) |
| Dec 2009 | $30.30 M(+114.6%) | $30.30 M(-6.8%) |
| Sept 2009 | - | $32.51 M(+292.5%) |
| June 2009 | - | $8.28 M(-29.4%) |
| Mar 2009 | - | $11.73 M(-16.9%) |
| Dec 2008 | $14.12 M(+37.7%) | $14.12 M(+120.2%) |
| Sept 2008 | - | $6.41 M(-20.9%) |
| June 2008 | - | $8.11 M(-2.1%) |
| Mar 2008 | - | $8.28 M(-19.2%) |
| Dec 2007 | $10.25 M(+23.2%) | $10.25 M(+44.6%) |
| Sept 2007 | - | $7.09 M(-9.0%) |
| June 2007 | - | $7.79 M(+22.9%) |
| Mar 2007 | - | $6.33 M(-23.9%) |
| Dec 2006 | $8.32 M(-51.5%) | $8.32 M(+329.0%) |
| Sept 2006 | - | $1.94 M(+3.6%) |
| June 2006 | - | $1.87 M(-15.6%) |
| Mar 2006 | - | $2.22 M(-87.1%) |
| Dec 2005 | $17.17 M(-4.0%) | $17.17 M(+244.9%) |
| Sept 2005 | - | $4.98 M(-28.0%) |
| June 2005 | - | $6.91 M(-41.5%) |
| Mar 2005 | - | $11.81 M(-34.0%) |
| Dec 2004 | $17.89 M(+32.9%) | $17.89 M(-9.4%) |
| Sept 2004 | - | $19.74 M(-10.5%) |
| June 2004 | - | $22.07 M(+68.1%) |
| Mar 2004 | - | $13.13 M(-2.5%) |
| Dec 2003 | $13.46 M(+1437.6%) | $13.46 M(+82.9%) |
| Sept 2003 | - | $7.36 M(+696.2%) |
| June 2003 | - | $924.20 K(-54.3%) |
| Mar 2003 | - | $2.02 M(+131.1%) |
| Dec 2002 | $875.40 K(-51.7%) | $875.40 K(-35.9%) |
| Sept 2002 | - | $1.36 M(-4.5%) |
| June 2002 | - | $1.43 M(+89.4%) |
| Mar 2002 | - | $754.80 K(-65.8%) |
| Dec 2001 | $1.81 M(-51.3%) | - |
| Sept 2001 | - | $2.21 M(-44.9%) |
| June 2001 | - | $4.00 M(+7.6%) |
| Mar 2001 | - | $3.72 M(+13.2%) |
| Mar 2001 | $3.72 M(-61.8%) | - |
| Dec 2000 | - | $3.29 M(-45.5%) |
| Sept 2000 | - | $6.03 M(-27.0%) |
| June 2000 | - | $8.25 M(-15.3%) |
| Mar 2000 | $9.74 M(+57.1%) | $9.74 M(+116.5%) |
| Dec 1999 | - | $4.50 M(+18.4%) |
| Sept 1999 | - | $3.80 M(-73.8%) |
| June 1999 | - | $14.50 M(+133.9%) |
| Mar 1999 | $6.20 M | $6.20 M(-29.5%) |
| Dec 1998 | - | $8.80 M |
FAQ
- What is Inovio Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Inovio Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Inovio Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of INO is $14.31 M
What is the all time high annual cash & cash equivalents for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual cash & cash equivalents is $250.73 M
What is Inovio Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, INO annual cash & cash equivalents has changed by -$32.02 M (-69.11%)
What is Inovio Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of INO is $21.69 M
What is the all time high quarterly cash and cash equivalents for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly cash and cash equivalents is $250.73 M
What is Inovio Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, INO quarterly cash and cash equivalents has changed by +$2.88 M (+15.33%)